A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors

Campos, S; Matulonis, U; Berlin, S; Horowitz, N; Liu, J; Krasner, C; Hang, L; Zarwan, C; Barry, W; Colella, T; Whalen, C; Shoni, M; Lundquist, C; Birrer, MJ; Penson, R

Campos, S (通讯作者)，Dana Farber Canc Inst, Gynecol Oncol Program, 450 Brookline Ave,YC1420, Boston, MA 02215 USA.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022; 27 (12): 1881

Abstract

Background The combination of paclitaxel to platinum remains the backbone of therapy in patients with advanced Mullerian tumors. In patients with newl......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索